Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Single and Multiple Doses of GS-9190, a Novel Anti-hepatitis C Virus Drug, in Treatment-naive Subjects with Chronic Hepatitis C Genotype 1 infection

Next Previous
X
Search
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Single and Multiple Doses of GS-9190, a Novel Anti-hepatitis C Virus Drug, in Treatment-naive Subjects with Chronic Hepatitis C Genotype 1 infection

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tegobuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 06 Nov 2007 Interim results were presented at AASLD 2007.
    • 29 Oct 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top